A Stable Isotope Study to Evaluate the Bioavailability of an Oat Protein-based Iron Delivery System

NCT05826899 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2024-04-11

No results posted yet for this study

Summary

In the current study, the OAT fibril - Fe SA (Fe-oat 1) and OAT fibril - Fe NaOH (Fe-oat 2) will both be studied in vivo, alone are oat fibril powder add iron supplement is soluble in water and oat fibril powder add iron supplement is soluble in water in a food matrix (acai puree and honey) to assess their promise as Fe food fortificants.

This first in human study to bioavailability assessment and adverse effect of the OAT fibril - Fe SA (Fe-oat 1), OAT fibril - Fe NaOH (Fe-oat 2) and in a food matrix to assess their promise as Fe food fortificants.

This study will be conducted with the following objectives.

1. To conduct a stable Fe isotope study to evaluate the bioavailability of OAT-Fe formulated using two reducing agents (Fe-oat 1 and Fe-oat-2) and compared to FeSO4.
2. To compare the performance of Fe-oat 1 and 2 in a food matrix containing Fe inhibitors, (acai puree and honey) in comparison to FeSO4 in a similar meal matrix.

Conditions

  • Bioavailability

Interventions

OTHER

54Fe SO4

4 mg of iron as FeSO4 labelled with 4 mg of 54Fe

OTHER

57Fe Oat-1

4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe

OTHER

58Fe Oat-2

4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.

OTHER

54 FeSO4 + Acai puree with honey

4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.

OTHER

57Fe Oat-1 + Acai puree with honey

4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.

OTHER

58Fe Oat-2 + Acai puree with honey

4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey

Sponsors & Collaborators

  • Mahidol University

    collaborator OTHER
  • Swiss Federal Institute of Technology

    collaborator OTHER
  • The Rainforest Company

    lead INDUSTRY

Principal Investigators

  • Sueppong Gowachirapant · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2024-01-31
Completion
2024-02-29

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05826899 on ClinicalTrials.gov